Curry Alyson M, White Dawanna S, Donu Dickson, Cen Yana
Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, United States.
Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, United States.
Front Physiol. 2021 Oct 21;12:752117. doi: 10.3389/fphys.2021.752117. eCollection 2021.
The human sirtuins are a group of NAD-dependent protein deacylases. They "erase" acyl modifications from lysine residues in various cellular targets including histones, transcription factors, and metabolic enzymes. Through these far-reaching activities, sirtuins regulate a diverse array of biological processes ranging from gene transcription to energy metabolism. Human sirtuins have been intensely pursued by both academia and industry as therapeutic targets for a broad spectrum of diseases such as cancer, neurodegenerative diseases, and metabolic disorders. The last two decades have witnessed a flood of small molecule sirtuin regulators. However, there remain relatively few compounds targeting human sirtuins in clinical development. This reflects the inherent issues concerning the development of isoform-selective and potent molecules with good drug-like properties. In this article, small molecule sirtuin regulators that have advanced into clinical trials will be discussed in details as "successful" examples for future drug development. Special attention is given to the discovery of these compounds, the mechanism of action, pharmacokinetics analysis, formulation, as well as the clinical outcomes observed in the trials.
人类沉默调节蛋白是一组依赖烟酰胺腺嘌呤二核苷酸(NAD)的蛋白质去酰基酶。它们能从包括组蛋白、转录因子和代谢酶在内的各种细胞靶点中的赖氨酸残基上“去除”酰基修饰。通过这些广泛的作用,沉默调节蛋白调控着从基因转录到能量代谢等一系列不同的生物学过程。作为癌症、神经退行性疾病和代谢紊乱等多种疾病的治疗靶点,人类沉默调节蛋白一直受到学术界和工业界的密切关注。在过去二十年里,出现了大量小分子沉默调节蛋白调节剂。然而,处于临床开发阶段的靶向人类沉默调节蛋白的化合物相对较少。这反映了在开发具有良好药物特性的亚型选择性和强效分子时存在的固有问题。在本文中,将详细讨论已进入临床试验的小分子沉默调节蛋白调节剂,作为未来药物开发的“成功”范例。特别关注这些化合物的发现、作用机制、药代动力学分析、制剂,以及在试验中观察到的临床结果。